Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Riad Sherif
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Beta
- 0.23
- Country
- CH
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 5.58
Financials
Revenue
$0.00-100.0%Net Income
$-9.97MEBITDA
$-9.48MFree Cash Flow
$-20.25MEPS (diluted)
$-0.16Shares Outstanding (diluted)
61.27M+87.2%Operating Expenses
$22.83MCash & Debt
$8.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-94.51M | $-1.81 |
| 2024 | $686.0K | $-85.78M | $-2.12 |
| 2023 | $0.00 | $-88.80M | $-2.97 |
| 2022 | $0.00 | $-38.70M | $-1.18 |
| 2021 | $0.00 | $-18.55M | $-0.57 |
| 2020 | $0.00 | $-14.87M | $-0.45 |
Valuation
OCShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·5d ago·Neutral
… share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on Octobe…
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017…
View source ↗ - Newszacks.com·7d ago·Negative
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS) Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026 HANGZHOU, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- UTStarcom Holdings Corp. (“UT” “UTStarcom” or the “Company”) (NASDAQ: UTSI), a global networking solutions provider, made its inaugural appearance at the 27th China International Optoelectronic Exposition (CIOE 2026), held September 9–11 at the Shenzhen World Exhibition & Convention Center. Exhibiting from a dedicated booth, UTStarcom highlighted its ext…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company's Board of Directors.
View source ↗ - Newszacks.com·35d ago·Positive
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON).
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
View source ↗ - Newsglobenewswire.com·57d ago·Negative
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”),
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.49 per share
Typical surprise -11.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.20 vs $-0.48beat
- Mon, May 11$-0.63 vs $-0.49miss
- Tue, Mar 3$-0.51 vs $-0.48miss
- Mon, Nov 10$-0.40 vs $-0.50beat
- Thu, Aug 21$-0.59 vs $-0.53miss
- Thu, May 8$-0.77 vs $-0.51miss
Estimates and results for OCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in OCS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.